The Jean Chrétien Pledge to Africa Act: Patent law and humanitarian aid

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 7, 2005, Pages 889-909

  Rimmer, Matthew ^a  

^a AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Access to essential medicines; AIDS; Compulsary licensing; Doha Declaration on the TRIPS Agreement and Public Health; HIV; Malaria; Patent law; Pharamceutical drug; Tuberculosis; World Trade Organization (WTO); WTO General Council decision

Indexed keywords

ANTIRETROVIRUS AGENT; CIPROFLOXACIN; ESSENTIAL DRUG; GENERIC DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFRICA; ARTICLE; CANADA; CONSENSUS; DEVELOPING COUNTRY; DRUG COST; DRUG LEGISLATION; DRUG MANUFACTURE; DRUG MARKETING; EPIDEMIC; EUROPE; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE ACCESS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; LICENSING; MALARIA; PATENT; SOCIOECONOMICS; TUBERCULOSIS;

EID: 22744444880     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.7.889     Document Type: Article

References (75)

1. FAUNCE T, DRAHOS P: Trade related aspects of intellectual property eights (TRIPS) and the threat to patients: a plea to doctors to respond internationally. Med. Law (1998) 17:299.
2. NIELSEN J, NICOL D: Pharmaceutical patents and developing countries: the conundrum of access and incentive. Australian Intellectual Property J. (2002) 13:289.
3. Global Intellectual Property Rights: Knowledge, Access and Development. Drahos P, Mayne R (Eds), Palgrave Macmillan, Hampshire (2002).
4. GERVAIS D: The TRIPS Agreement: Drafting History and Analysis (2nd Ed.), Sweet and Maxwell, London, UK (2003).
5. SELL S: Private Power, Public Law: the Globalization of Intellectual Property Rights. Cambridge University Press, Cambridge, UK (2003).
6. OPDERBECK D: Patents, essential medicines, and the innovation game. Vanderbilt Law Rev. in press.
7. MAYNE R: The global campaign on patents and access to medicines: an Oxfam perspective. In: Global Intellectual Property Rights: Knowledge, Access and Development. Drahos P, Mayne R (Eds), Palgrave Macmillan, Hampshire, UK (2002):245.
8. MCGREAL C: South Africa's sick await judgment day. The Guardian Weekly (8-14 March 2001):1.
9. O'LOUGHLIN E: Politicians and drug firms playing with lives. Cynical Squabble Over AIDS. The Sydney Morning Herald (10 March 2001):20-21.
10. O'LOUGHLIN E: New hope on AIDS drugs for the poor. The Sydney Morning Herald (19 April 2001):1.
11. NASH D: South Africa's Medicines and Related Substances Control Amendment Act of 1997. Berkeley Tech. Law J. (2000) 15:485.
12. WOOLDRIDGE F: Analysis: affordable medicines - TRIPs and United States policies. Intellectual Property Quarterly (2000):103.
13. BOMBACH K: Can South Africa fight AIDS? Reconciling the South African Medicines and Related Substances Act with TRIPS agreement. Boston Univ. Int. Law J. (2001) 19(2)273-306.
14. Brazil - measures affecting patent protection. WT/DS199/4, G/L/454, IP/D/23/Add.1 (19 July 2001):01-3506.
15. CHAMP P, ATTARAN A: Patent rights and local working under the WTO TRIPS Agreement: an analysis of the US-Brazil patent dispute. Yale J. Int. Law. (2002) 27(2):365-393.
16. RESNIK D, DE VILLE K: Bioterrorism and patent rights: 'compulsory licensure' and the case of Cipro. Am. J. Bioethics. (2002) 2(3):29-39.
17. GOLDBERG R: Terrorising Patents. Expert Opin. Ther. Patents (2002) 12(3):329-330.
18. FERRONE J: Compulsory licensing during public health crises: bioterrotism's mark on global pharmaceutical patent protection. Suffolk Transnational Law Rev. (2003) 26:385.
19. WTO Doc WT/MIN (01)IDEC/2 (2001).
20. ABBOTT F: The Doha Declaration on the TRIPS Agreement and Public Health: lighting a dark corner at the WTO. J. Int. Economic Law (2002) 5:469-505.
21. GATHII JT: The legal status of the Doha declaration on TRIPS and public health under the Vienna Convention on the Law of Treaties. Harvard J. Law Tech. (2002) 5(2):291-317.
22. MURTHY D: The future of compulsory licensing: deciphering the Doha Declaration on the TRIPS Agreement and public health. Am. Univ. Int. Law Rev. (2002) 17(6):1299-1346.
23. ROTT P: The Doha Declaration - good news for public health. Intellectual Property Quarterly (2003) 3:284-311.
24. ATTARAN A: Assessing and answering paragraph 6 of the Doha Declaration on the TRIPS Agreement and public health: the case for greater flexibility and a non-justiciability solution. Emory Int. Law Rev. (2003) 17:743-780,
25. MATTHEWS D: WTO decision on implementation of paragraph 6 of the Doha Declaration on the TRIPS Agreement and public health: a solution to the access to essential medicines problem? J. Int. Economic Law (2004) 7:73-107.
26. BRAITHWAITE J, DRAHOS P: Global Business Regulation. Cambridge University Press, Cambridge. (2000):15-26.
27. MARTIN P: Prime Minister's statement on amendments to bill C-9, The Jean Chrétien Pledge to Africa Act. Ottawa, Ontario. (20 April 2004).
28. ABBOTT F: Testimony before the Standing Committee on Industry, Science and Technology. House of Commons, 37th Parliament, 3rd Session (10 March 2004).
29. OUTTERSON K: Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale J. Health Policy Law Ethics (2004) 5:193.
30. Schedule Two; Jean Chréetien Pledge to Africa. Canada (2004).
31. Schedule Three; Jean Chréetien Pledge to Africa. Canada (2004).
32. Schedule Four; Jean Chrétien Pledge to Africa. Canada (2004).
33. WHO: Statement of the World Health Organization on Canada's proposed legislative changes for medicines. Geneva. (7 November 2003).
34. ELLIOTT R: Global Access to Treatment: Canada's Bill C-9 and the compulsory licensing of pharmaceuticals for export to countries in need. Canadian HIV-AIDS Legal Network (July 2004).
35. ELLIOTT R, MEMBERS OF THE GLOBAL ACCESS TREATMENT CAMPAIGN: TRIPS From Doha to Cancún. to Ottawa: WTO patent rules and Canadian civil society advocacy for global treatment access. 15th World AIDS Conference. Bangkok, Thailand. (July 2004).
36. OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE: US and Canada agree to assist poor countries access to medicine. San Antonio, Texas (16 July 2004).
37. WTO PANEL REPORT: WT/DS170/R-Canada-Patent Protection of Pharmaceuticals, complaint by the United States (5 May 2000)
38. WTO PANEL REPORT: WT/DS114/R-Canada-Patent Protection of Pharmaceutical Products complaint by the European Communities and their Member States (17 March 2000).
39. COMMISSION OF THE EUROPEAN COMMUNITIES: Supra note 49.
40. RICHARD ELLIOTT: Supra note 37.
41. Glaxo Group Ltd v. Dowelhurst Ltd (2003) E.W.H.C. 3060 (High Court, Ch. Div. 2003) available at 2003 WL 23014797.
42. Glaxo Group Ltd v. Dowelhurst Ltd (2004) E.T.M.R. 39 (July 31, 2003) available at 2003 WL 21729286.
43. DAN ISAACS: GSK Aims to Stop Aids Profiteers. BBC News. (21 February 2005).
44. KEVIN OUTTERSON: Pharmaceutical arbitrage: balancing access and innovation in international prescription drug markets. Yale Journal Health Policy, Law and Ethics (2004) 5:193.
45. France to introduce legislation for generic exports. AFP (22 November 2004).
46. Hearing on TRIPS and Access to Medicines, Committee on International Trade, European Parliament, Brussels (18 January 2005).
47. BAINS P: Hearing on TRIPS and Access to Medicines, Committee on International Trade, European Parliament, Brussels (18 January 2005).
48. HADDAD W: Hearing on TRIPS and Access to Medicines, Committee on International Trade, European Parliament, Brussels, (18 January 2005).
49. 'T HOEN E: Hearing on TRIPS and Access to Medicines, Committee on International Trade, European Parliament, Brussels (18 January 2005).
50. DUTFIELD G: Intellectual Property Rights And The Life Science Industries. Aldershot, Ashgate. (2003): 109.
51. GRUEN N, BRUCE I, PRIOR G: Extending Patent Life: Is It In Australia's Economic Interests? Commonwealth Government: Productivity Commission (June 1996).
52. Aktiebolaget Hässle v Alphapharm Pty Ltd (2002) 212 CLR 411.
53. Aktiebolaget Hässle v Alphapharm Pty Ltd (2002) 212 CLR 411 at 449-450.
54. SENATE SELECT COMMITTEE ON THE FREE TRADE AGREEMENT BETWEEN AUSTRALIA AND THE UNITED STATES OF AMERICA: Final Report. Canberra: Australian Parliament (August 2004): 137.
55. FRASER A: Fears FTA will stop vital drugs. The Canberra Times (30 June 2004): 13.
56. FAUNCE T: Hearing. Senate Select Committee on the Free Trade Agreement Between Australia and the United States of America (21 June 2004):7.
57. LAWSON C, PICKERING C: 'TRIPs-Plus' patent privileges - an intellectual property 'Cargo Cult' in Australia. Prometheus. (2004) 22(4):355.
58. DEADY S: Hearing. Senate Select Committee on the Free Trade Agreement Between Australia and the United States of America (21 June 2004):18.
59. STEPHEN DEADY: Hearing. Senate Select Committee on the Free Trade Agreement Between Australia and the United States of America (21 June 2004):53.
60. MARTIN QUINN: Public Hearing. Intellectual property, Senate Select Committee on the United States-Australia Free Trade Agreement (6 July 2004).
61. Senate Select Committee on the Free Trade Agreement between Australia and the United States of America, Final Report. Canberra. Australian Parliament (August 2004):135.
62. AUSTRALIAN LAW REFORM COMMISSION: Gene Patenting and Human Health: Discussion Paper 68, supra note 120 at 731.
63. AUSTRALIAN LAW REFORM COMMISSION: Gene Patenting and Human Health: Discussion Paper 68, supra note 120 at 730.
64. AUSTRALIAN LAW REFORM COMMISSION: Genes and Ingenuity: Gene Patenting and Human Health. Report 99, supra note 120 at 629.
65. AUSTRALIAN LAW REFORM COMMISSION: Genes and Ingenuity: Gene Patenting and Human Health. Report 99, supra note 120 at 630.
66. KANAKO TAKAHARA: Japan urged to take lead in easing of drug patents. Japan Times (14 February 2003).
67. NATH K: Statement on the ordinance relating to patents (Third Amendment). (27 December 2004).
68. India to curb export of cheap copycat generic drugs. AFP (25 December 2004).
69. MÉDECINS SANS FRONTIÈRES: Sources of affordable generic medicines drying up? India should ensure global access to medicines. (15 March 2005).
70. MéEDECINS SANS FRONTIÈRES: The beginning of the end of affordable genetics. (22 March 2005)
71. MÉDECINS SANS FRONTIÈRES: Now that the dust gas settled: the consequences of the new Indian patents act. (29 March 2005).
72. 'T HOEN E: Hearing on TRIPS and access to medicines. Committee on International Trade, European Parliament, Brussels (18 January 2005).
73. KAMPF R: Hearing on TRIPS and access to medicines. Committee on International Trade, European Parliament (18 January 2005).
74. LOVE J, HUBBARD T: Make drugs affordable: replace TRIPS-Plus with R&D. Bridges (2004) 6:3-4
75. RIMMER M: The race to Patent the SARS virus: The TRIPS agreement and access to essential medicines. Melbourne J. Int. Law (October 2004) 5(2):335-374.